Scott L. Burrows's most recent trade in Spyre Therapeutics Inc. was a trade of 7,500 Common Stock done at an average price of $14.5 . Disclosure was reported to the exchange on July 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.50 per share. | 01 Jul 2026 | 7,500 | 105,494 (0%) | 0% | 14.5 | 108,750 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 7,500 | 352,357 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 87.55 per share. | 01 Jul 2026 | 5,775 | 99,719 (0%) | 0% | 87.5 | 505,601 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 88.37 per share. | 01 Jul 2026 | 1,725 | 97,994 (0%) | 0% | 88.4 | 152,438 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2026 | 15,000 | 359,857 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.50 per share. | 25 Jun 2026 | 15,000 | 112,994 (0%) | 0% | 14.5 | 217,500 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 87.14 per share. | 25 Jun 2026 | 10,000 | 97,994 (0%) | 0% | 87.1 | 871,400 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 87.12 per share. | 25 Jun 2026 | 5,000 | 107,994 (0%) | 0% | 87.1 | 435,600 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 7,500 | 374,857 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.50 per share. | 01 Jun 2026 | 7,500 | 105,494 (0%) | 0% | 14.5 | 108,750 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 72.06 per share. | 01 Jun 2026 | 3,100 | 97,994 (0%) | 0% | 72.1 | 223,386 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.77 per share. | 01 Jun 2026 | 2,599 | 101,094 (0%) | 0% | 70.8 | 183,931 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 69.75 per share. | 01 Jun 2026 | 1,801 | 103,693 (0%) | 0% | 69.8 | 125,620 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.50 per share. | 01 May 2026 | 12,500 | 110,494 (0%) | 0% | 14.5 | 181,250 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2026 | 12,500 | 382,357 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 71.37 per share. | 01 May 2026 | 12,500 | 97,994 (0%) | 0% | 71.4 | 892,125 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.50 per share. | 01 Apr 2026 | 7,500 | 105,494 (0%) | 0% | 14.5 | 108,750 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 7,500 | 394,857 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.21 per share. | 01 Apr 2026 | 6,200 | 99,294 (0%) | 0% | 49.2 | 305,102 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 49.98 per share. | 01 Apr 2026 | 1,300 | 97,994 (0%) | 0% | 50.0 | 64,974 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.26 per share. | 02 Sep 2025 | 18,428 | 97,994 (0%) | 0% | 16.3 | 299,639 | Common Stock |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 95,500 | 95,500 | - | - | Stock Option (Right to Buy) | |
| Spyre Therapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.17 per share. | 03 Sep 2024 | 18,531 | 116,422 (0%) | 0% | 28.2 | 522,074 | Common Stock |
| Aeglea BioTherapeutics Inc | Scott Burrows L. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Aeglea BioTherapeutics Inc | Burrows L. Scott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2023 | 134,953 | 134,953 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.26 per share. | 06 Mar 2023 | 291 | 59,115 (0%) | 0% | 15.3 | 4,442 | Common Stock |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 55,800 | 55,800 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 21,000 | 59,406 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.82 per share. | 28 Feb 2023 | 1,416 | 38,424 (0%) | 0% | 15.8 | 22,399 | Common Stock |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.17 per share. | 28 Feb 2023 | 416 | 39,840 (0%) | 0% | 16.2 | 6,725 | Common Stock |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.50 per share. | 28 Feb 2023 | 18 | 38,406 (0%) | 0% | 16.5 | 297 | Common Stock |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2022 | 5,000 | 37,277 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 16 Sep 2022 | 5,000 | 40,256 (0%) | 0% | 1.7 | 8,403 | Common Stock |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 35,300 | 35,300 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 13,300 | 35,559 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.86 per share. | 03 Mar 2022 | 293 | 35,266 (0%) | 0% | 16.9 | 4,940 | Common Stock |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.40 per share. | 03 Mar 2022 | 10 | 35,256 (0%) | 0% | 16.4 | 164 | Common Stock |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.75 per share. | 01 Mar 2022 | 420 | 22,259 (0%) | 0% | 17.8 | 7,456 | Common Stock |
| Arcutis Biotherapeutics Inc | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.07 per share. | 27 Dec 2021 | 12,560 | 22,679 (0%) | 0% | 20.1 | 252,139 | Common Stock |